244 related articles for article (PubMed ID: 35532298)
1. Smoldering multiple myeloma: Reviewing the rationale for intervention.
Gertz M
Leuk Lymphoma; 2022 Sep; 63(9):2033-2040. PubMed ID: 35532298
[TBL] [Abstract][Full Text] [Related]
2. Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
Rajkumar SV; Bergsagel PL; Kumar S
Hematol Oncol Clin North Am; 2024 Apr; 38(2):293-303. PubMed ID: 38158241
[TBL] [Abstract][Full Text] [Related]
3. Progress in the Management of Smoldering Multiple Myeloma.
Schmidt TM; Callander NS
Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
Schmidt T; Callander N
J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.
Hughes D; Yong K; Ramasamy K; Stern S; Boyle E; Ashcroft J; Basheer F; Rabin N; Pratt G
Br J Haematol; 2024 Apr; 204(4):1193-1206. PubMed ID: 38393718
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
González-Calle V; Mateos MV
Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
[TBL] [Abstract][Full Text] [Related]
7. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
Kunacheewa C; Manasanch EE
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
[TBL] [Abstract][Full Text] [Related]
8. Smoldering multiple myeloma 40 years later: a story of unintended disease.
Yavorkovsky LL
Expert Rev Hematol; 2021 Feb; 14(2):149-153. PubMed ID: 33430658
[No Abstract] [Full Text] [Related]
9. Smoldering multiple myeloma current treatment algorithms.
Rajkumar SV; Kumar S; Lonial S; Mateos MV
Blood Cancer J; 2022 Sep; 12(9):129. PubMed ID: 36064707
[TBL] [Abstract][Full Text] [Related]
10. The difficult business of assessing new therapies for smouldering multiple myeloma.
Zonder JA
Br J Haematol; 2018 Aug; 182(4):463-464. PubMed ID: 29767407
[No Abstract] [Full Text] [Related]
11. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
Maciocia N; Wechalekar A; Yong K
Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
[TBL] [Abstract][Full Text] [Related]
12. Smoldering multiple myeloma - Past, present, and future.
Mann H; Katiyar V; Varga C; Comenzo RL
Blood Rev; 2022 Mar; 52():100869. PubMed ID: 34312016
[TBL] [Abstract][Full Text] [Related]
13. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Musto P; Engelhardt M; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS
Haematologica; 2021 Nov; 106(11):2799-2812. PubMed ID: 34261295
[TBL] [Abstract][Full Text] [Related]
14. Risk Stratification of Precursors to Multiple Myeloma in 2020.
Chudasama R; Barth P
R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
[TBL] [Abstract][Full Text] [Related]
15. [Smoldering multiple myeloma].
Fouquet G; Guidez S; Herbaux C; Demarquette H; Leleu X
Rev Med Interne; 2014 Apr; 35(4):243-9. PubMed ID: 24050785
[TBL] [Abstract][Full Text] [Related]
16. Smoldering multiple myeloma: biology, clinical manifestations and management.
Nsiala L; Bobin A; Levy A; Gruchet C; Sabirou F; Gardeney H; Cailly L; Manier S; Moya N; Tomowiak C; Guidez S; Leleu X; Decaux O
Leuk Lymphoma; 2022 Mar; 63(3):518-529. PubMed ID: 34672244
[TBL] [Abstract][Full Text] [Related]
17. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L
Curr Treat Options Oncol; 2006 May; 7(3):237-45. PubMed ID: 16615879
[TBL] [Abstract][Full Text] [Related]
18. Smouldering multiple myeloma: To seek or not to seek? To treat or not to treat. That is the question.
Vaxman I; Gatt ME
Br J Haematol; 2024 Apr; 204(4):1141-1142. PubMed ID: 38429858
[TBL] [Abstract][Full Text] [Related]
19. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
[TBL] [Abstract][Full Text] [Related]
20. Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions.
Chojnacka M; Diamond B; Landgren O; Maura F
Semin Oncol; 2022 Feb; 49(1):11-18. PubMed ID: 35168813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
